Clinical trial • Phase I • Oncology

LB-208 for Solid tumor | Lymphoma

Phase I trial of LB-208 for Solid tumor | Lymphoma. 57 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Solid tumor | Lymphoma
Trial Stage
Phase I
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
05-03-2024
First CTIS Authorization Date
11-06-2024

Trial design

Phase I trial across 1 site in Spain.

Single Multiple Or Escalation Dose Combined
Yes
Target Sample Size
57

Eligibility

Recruits 57 Vulnerable population selected; no details on consent or assent handling available in the record..

Vulnerable Population
Vulnerable population selected; no details on consent or assent handling available in the record.

Recruitment

Planned Sample Size
57
Recruitment Window Months
38

Geography

Total Number Of Sites
1
Total Number Of Participants
57

Spain

Earliest CTIS Part Ii Submission Date
30-05-2024
Latest Decision Or Authorization Date
02-02-2026
Processing Time Days
613
Number Of Sites
1
Number Of Participants
57

Sites

Site Name
Hospital Universitari Vall D Hebron
Department Name
Oncology
Contact Person Name
Irene Braña
Contact Person Email
ibrana@vhio.net

Sponsor

Primary sponsor

Full Name
Leukos Biotech S.L.
Organisation Type
Pharmaceutical company
Country Of Registered Address
Spain

Investigational products

Investigational Product Name
LB-208 (HTR1B antagonist)
Active Substance
LB-208
Modality
Small molecule
First In Human
Yes

Related trials

Other published trials that may interest you.